Sedana Medical Q3: A blow but no curtains-down event - Redeye

Redeye lowers its fair value range following a reconsideration of its financial estimates (following the shifted US launch timeline) and an increased WACC. We argue that investor interest in the share is bound to be low for some time, but its long-term US prospects are still intriguing.

Länk till analysen i sin helhet: https://www.redeye.se/research/1049106/sedana-medical-q3-a-blow-but-no-curtains-down-event?utm_source=finwire&utm_medium=RSS